‍

Daewoong Pet will hold an offline symposium titled "Innovative Approaches to Digestive Disease Treatment: Personalized Treatment Through Rapid-Release Pancreatin" on the 26th at Daewoong Pharmaceutical's Bear Hall in Samseong-dong, Gangnam, Seoul. This event will target veterinarians and pet industry professionals, and aims to share the latest insights on diagnosing and treating pancreatic diseases in pets.

The symposium will involve in-depth discussions with veterinarians and industry experts on the diagnosis and treatment of pancreatic diseases, with a focus on the impact of pancreatic digestive enzymes on chronic and acute pancreatitis. The goal is to improve the quality of life of pets suffering from these conditions.

The event will kick off with an introduction by Daewoong Pet CEO Lee Hyo-jun, followed by lectures on the following topics:

Latest Insights on Diagnosis and Treatment of Fatty Stool in Dogs (Professor Ahn Ju-hyun, Kangwon National University)

Effects of Pancreatic Digestive Enzymes on Chronic and Acute Pancreatitis in Elderly Pets with Chronic Diseases (Dr. Lim Yoon-ji, VIP Pet Cancer Center)

Treatment and Management Directions for Chronic and Acute Pancreatitis Patients (Dr. Kim Tae-hee, Gyeonggi 24-hour SKY Animal Hospital)

Role of Digestive Enzymes in Managing Pancreatic Diseases and Indigestion Symptoms (Dr. Jang Bong-hwan, Good Morning Pet Animal Hospital)

Symposium registration can be completed by scanning the QR code on the event poster or through a separate URL.

Daewoong Pet has launched Epicle (EPICLE), a pancreatic enzyme supplement containing pancreatin, a digestive enzyme that breaks down starch, protein, and fat, and lipase, a fat-digesting enzyme produced only in the pancreas. Epicle is designed to improve indigestion, nutrient absorption issues, and pancreatic pain caused by exocrine pancreatic dysfunction, as well as help resolve fatty stools that result from undigested fat being expelled in the feces.

Notably, Epicle is formulated as a rapid-release supplement, ensuring immediate effect upon consumption, taking into account the impaired digestive function of pets with pancreatic issues. Daewoong Therapeutics’ patented technology stabilizes the enzymes with an alkaline stabilizer to prevent them from being deactivated by stomach acid, allowing them to reach the duodenum effectively. The small size (7mm x 5mm) of the product also makes it easy for small pets to ingest.

CEO Lee Hyo-jun stated,

"This symposium is held to provide veterinarians and industry professionals with accurate information on pancreatic diseases in pets. Our hope is to help pet owners maintain their beloved pets' health for a long time. Daewoong Pet will continue to carry out various activities aimed at ensuring the healthy coexistence of pets and their owners."